On November 5, 2026, thoracic oncology congresses highlighted Augtyro® (Repotrectinib 160 mg capsules) developed by Bristol Myers Squibb as the next-generation macrocyclic tyrosine kinase inhibitor redefining outcomes in ROS1-positive non-small cell lung cancer (NSCLC) and NTRK fusion-positive solid tumors.

First-generation TKIs (crizotinib, entrectinib) routinely fail over time due to solvent-front resistance mutations—predominantly ROS1 G2032R—and poor blood-brain barrier penetrance. Augtyro circumvents both obstacles through compact macrocyclic spatial engineering.

Through Critical Kare Pharma, certified authentic bottles of Augtyro Repotrectinib 160mg Capsules are delivered directly to treating oncologists and hospital pharmacies internationally.

Macrocyclic Structure & Solvent-Front Overcoming

• Compact Rigid Scaffold: Repotrectinib's macrocyclic ring fits tightly inside the ATP-binding pocket without clashing with bulky mutated side chains at the solvent front (such as ROS1 G2032R or TRKA G595R).
• Nanomolar Potency: Demonstrates over 90-fold greater potency against wild-type and solvent-front mutant ROS1 kinases compared to crizotinib.
• CNS Penetration: Readily crosses the blood-brain barrier, eliciting robust, durable responses in patients with baseline brain metastases.

Pivotal TRIDENT-1 Clinical Evidence

• TKI-Naive ROS1-Positive NSCLC: Confirmed objective response rate of 79% with median duration of response exceeding 34 months.
• TKI-Pretreated with Solvent-Front Mutation: Achieved an unprecedented 59% objective response rate in patients harboring the ROS1 G2032R mutation who progressed on prior TKIs.
• Intracranial Response: 89% intracranial response rate in TKI-naive patients with measurable baseline intracranial lesions.

Dosing & Access

Recommended starting dose is 160 mg orally once daily for 14 days, escalating to 160 mg twice daily. Dizziness and paresthesia are managed with gradual titration. Available via Critical Kare Pharma under official named-patient import licenses globally.